Publication: Emerging Pharmacological Therapies for the Irritable Bowel Syndrome
1
Issued Date
2011-03-01
Resource Type
ISSN
08898553
Other identifier(s)
2-s2.0-79951563809
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gastroenterology Clinics of North America. Vol.40, No.1 (2011), 223-243
Suggested Citation
Monthira Maneerattanaporn, Lin Chang, William D. Chey Emerging Pharmacological Therapies for the Irritable Bowel Syndrome. Gastroenterology Clinics of North America. Vol.40, No.1 (2011), 223-243. doi:10.1016/j.gtc.2010.12.002 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/12624
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Emerging Pharmacological Therapies for the Irritable Bowel Syndrome
Abstract
The irritable bowel syndrome (IBS) is a symptom-based disorder defined by the presence of abdominal pain and altered bowel habits. Clinical presentations of IBS are diverse, with some patients reporting diarrhea, some constipation, and others a mixture of both. Like the varied clinical phenotypes, the pathogenesis of IBS is also diverse. IBS is not a single disease entity, but rather likely consists of several different disease states. This fact has important implications for the choices and efficacy of IBS treatment. This article reviews the IBS drugs that have reached phase II or III clinical trials. © 2011 Elsevier Inc.